Business Standard

Biocon rises on healthy Q3 earnings

Q3 net profit up 9% year-on-year at Rs 93 crore against an average analyst expectation of Rs 86 crore due to higher sales.

Related News

Biocon is trading higher by 4% to Rs 277 after reporting 9% year-on-year (yoy) rise in net profit at Rs 93 crore for the third quarter ended December 2012 (Q3) driven by period growth in different business verticals.

“Total sales of the company grew by 23% to Rs 635 crore from Rs 517 crore previous year,” said in a statement.

Analyst on an average had expected a net profit of Rs 86 crore and net sales of Rs 613 crore from the India’s largest biotechnology company by revenue.

“We have performed well across all our business verticals. We continue to gain market share for biosimilar insulins in global markets, which now accounts for a significant part of our business,” chairman and managing director said in a statement.

The company has received approval from the DCGI (Drugs Controller General of India) for our monoclonal antibody, Itolizumab, indicated for psoriasis. This is a significant milestone that enhances the value of this late-stage asset, added Kiran Mazumdar-Shaw.

The stock opened at Rs 268 and hit a high of Rs 278 on NSE. A combined 513,708 shares have already changed hands on the counter so far on both the exchanges.

 

Read more on:   
|
|

Read More

UCO Bank slips on declining net

Shares of UCO Bank has slumped after the bank posted a sharp drop in net profit for the third quarter ended December 31, 2012.

Recommended for you

Advertisements

Quick Links

Market News

Sensex sheds 499 pts; Bank of Baroda, ICICI Bank results disappoint

Coal India drops 4 per cent even as its Rs 22,000 crore offer for sale fully subscribed; Nifty sheds 143 pts

Coal India 10% stake sale fully covered

Investors bid for 662 million shares of Coal India versus the issue size of 631.6 million shares

Sensex ends below 29,200; BSE Bankex down 3%

The 30-share Sensex provisionally ended down by 482 points at 29,199 and the 50-share Nifty slipped 130 points at 8,823.

Strides Arcolab gains on USFDA OKs oral dosage facility at Bangalore

The stock was up 4% at Rs 933 on BSE.

ICICI Bank dips over 5% post Q3 results

At 1445 hours, the stock was down nearly 6% at Rs 358 on National Stock Exchange.

 

Back to Top